New Feature: A New Era for News on Finviz

Upstream Bio

Contributing Author

Recent Articles by Upstream Bio

Feb-26	Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 UPB GlobeNewswire
Feb-25	Upstream Bio to Participate in Upcoming March Investor Conferences UPB GlobeNewswire
Feb-11	Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma UPB -47.18% GlobeNewswire
Feb-10	Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma UPB +6.47% GlobeNewswire
Jan-05	Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference UPB GlobeNewswire
Nov-25	Upstream Bio to Participate in Upcoming December Investor Conferences UPB +10.67% GlobeNewswire
Nov-05	Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress UPB GlobeNewswire
Oct-31	Upstream Bio to Participate in Upcoming November Investor Conferences UPB GlobeNewswire
Sep-30	Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress UPB +8.48% GlobeNewswire
Sep-09	Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum UPB GlobeNewswire
Sep-02	Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) UPB +18.27% GlobeNewswire
Sep-01	Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) UPB GlobeNewswire
Aug-06	Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress UPB +7.87% GlobeNewswire
Jul-08	Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) UPB GlobeNewswire
Jun-15	Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor UPB GlobeNewswire
Jun-05	Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 UPB GlobeNewswire
Jun-04	Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference UPB GlobeNewswire
May-20	Upstream Bio Appoints Stacy Price as Chief Technology Officer UPB GlobeNewswire
May-06	Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs UPB -5.41% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.